ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
19 hedge funds and large institutions have $10.5M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
167% more call options, than puts
Call options by funds: $8K | Put options by funds: $3K
10% less funds holding
Funds holding: 21 → 19 (-2)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
57% less capital invested
Capital invested by funds: $24.6M → $10.5M (-$14.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.77M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$1.43M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$85.1K |
| 4 |
Renaissance Technologies
New York
|
+$10.8K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$532 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.21M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$307K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$295K |
| 4 |
Barclays
London,
United Kingdom
|
-$219K |
| 5 |
Millennium Management
New York
|
-$136K |
ASLN Hedge Fund Activity: Q3 2023 in Review
19 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2023, worth a combined $10.5M — down 57% from $24.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ASLN and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Tang Capital Management, adding an estimated $1.77M. The largest seller was Vivo Capital, cutting an estimated $5.21M.
- 19 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2023, down from 21 in Q2 2023.
- Funds reported $10.5M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2023, down 57% quarter-over-quarter.
- 2 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2023 and 4 closed out, a net change of -2 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q3 2023 was Tang Capital Management, an estimated $1.77M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2023 was Vivo Capital, an estimated $5.21M sold.
Based on aggregated 13F filings for Q3 2023.